January 26, 2009 - SenoRx Inc. said today that it has extended its international reach to encompass five additional global markets, and will now market its EnCor vacuum-assisted breast biopsy and GelMark breast biopsy tissue markers through distributors in Egypt, Greece, Poland, Saudi Arabia, Thailand, Turkey and the United Arab Emirates.

SenoRx is partnering with local in-country distributors who have breast imaging and/or interventional radiology franchises in select markets. SenoRx has previously established partnering relationships with distributors in Australia, Austria, Belgium, Denmark, Finland, France, Germany, Hong Kong, Iceland, Ireland, Italy, Luxembourg, Mexico, The Netherlands, Norway, Portugal, Russia, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan and the United Kingdom.

EnCor and SenoRx breast tissue biopsy markers have previously received the necessary regulatory clearances in countries within the European Economic Community and in all of the other countries that SenoRx has established distribution channels.

For more information: ww.senorx.com


Additional Content

News | Breast Biopsy Systems

July 7, 2021 — GE Healthcare announced the installation of Serena Bright in five hospitals and radiology centers around ...

Time July 07, 2021
arrow
News | Breast Imaging

January 4, 2021 — Hologic, Inc. announced it has completed the acquisition of SOMATEX Medical Technologies GmbH, a ...

Time January 04, 2021
arrow
News | Prostate Cancer

According to the American Cancer Society, approximately one in nine men will be diagnosed with prostate cancer in their lifetime. It’s both the second most common cancer and second most common cause of cancer death in American men. Early detection is critical and can increase a man’s chances of survival.

Time August 20, 2019
arrow
News | Biopsy Systems

Dune Medical Devices has just completed the first in-man cases for Smart Biopsy, its percutaneous soft tissue biopsy device which leverages the real-time tissue characterization capability of its radiofrequency (RF) spectroscopy technology.

Time March 29, 2019
arrow
Technology | Interventional Radiology

The U.S. Food and Drug Administration (FDA) cleared the Ion endoluminal system from Intuitive Surgical Inc. to enable minimally invasive biopsy in the peripheral lung.

Time February 20, 2019
arrow
Subscribe Now